IN8bio (INAB) vs Jasper Therapeutics (JSPR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
IN8bio (INAB) has outperformed Jasper Therapeutics (JSPR) over the past year, losing 42.7% versus a loss of 76.7%. Over five years, INAB leads with a -99.2% price change compared with -99.7% for JSPR. Jasper Therapeutics is the larger company by market cap ($18.6 million vs $13.6 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INAB | JSPR |
|---|---|---|
| Share price | $1.38 | $0.56 |
| Market cap | $13.60M | $18.63M |
| 1-day change | -1.43% | -1.70% |
| YTD return | -41.03% | -69.40% |
| 1-year return | -42.74% | -76.67% |
| 5-year return | -99.23% | -99.66% |
| EPS (TTM) | $-1.62 | $-1.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.73 | $2.69 |
| 52-week low | $0.88 | $0.315 |
| Distance from 52-week high | -49.45% | -79.18% |
| Analyst consensus | none | none |
| Avg. price target upside | +407.25% | +3471.43% |
| Average volume | 58.36K | 1.37M |
| Shares outstanding | 9.86M | 33.27M |
| Employees | 18 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INAB has outperformed JSPR by 33.9 percentage points over the past year.
About IN8bio
INAB stock →IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees
About Jasper Therapeutics
JSPR stock →Jasper Therapeutics, Inc., a clinical stage biotechnology company, focuses on the design and development of therapies to treat immune-mediated diseases. It is advancing a pipeline of medicines, including KP-104, a dual-complement inhibitor that has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under evaluation in other unmet need nephrology disorders; Briquilimab is an anti-KIT antibody, which has demonstrated clinical results as a conditioning agent for stem cell transplant and mast cell mediated diseases, such as chronic urticarias and allergic asthma; and KP-701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
INAB vs JSPR FAQ
Which is bigger, IN8bio or Jasper Therapeutics?
Jasper Therapeutics (JSPR) is larger, with a market capitalization of $18.63M compared with $13.60M for IN8bio (INAB).
Which stock has performed better over the past year, INAB or JSPR?
INAB returned -42.74% over the past 12 months, compared with -76.67% for JSPR (price return, excluding dividends). Past performance does not predict future results.
Are IN8bio and Jasper Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.